1. Home
  2. MHD vs FULC Comparison

MHD vs FULC Comparison

Compare MHD & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniHoldings Fund Inc.

MHD

Blackrock MuniHoldings Fund Inc.

HOLD

Current Price

$11.69

Market Cap

617.9M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$7.90

Market Cap

535.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHD
FULC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
617.9M
535.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MHD
FULC
Price
$11.69
$7.90
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
440.6K
1.0M
Earning Date
01-01-0001
04-30-2026
Dividend Yield
4.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.79
$2.49
52 Week High
$12.05
$15.74

Technical Indicators

Market Signals
Indicator
MHD
FULC
Relative Strength Index (RSI) 57.61 50.85
Support Level $11.63 $6.35
Resistance Level $11.80 $8.17
Average True Range (ATR) 0.12 0.49
MACD 0.03 0.22
Stochastic Oscillator 96.36 77.05

Price Performance

Historical Comparison
MHD
FULC

About MHD Blackrock MuniHoldings Fund Inc.

Blackrock Muniholdings Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The fund mainly invests its managed assets in municipal bonds rated investment grade or, if unrated, are deemed to be of comparable quality by the investment adviser at the time of investment. Its investment portfolio is mainly comprised of long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: